Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Insider Sells $421,050.00 in Stock

Y-mAbs Therapeutics, Inc. (NASDAQ:YMABGet Free Report) insider Thomas Gad sold 35,000 shares of the firm’s stock in a transaction dated Monday, June 10th. The shares were sold at an average price of $12.03, for a total transaction of $421,050.00. Following the completion of the sale, the insider now owns 197,681 shares of the company’s stock, valued at approximately $2,378,102.43. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Thomas Gad also recently made the following trade(s):

  • On Thursday, May 23rd, Thomas Gad sold 7,351 shares of Y-mAbs Therapeutics stock. The shares were sold at an average price of $13.00, for a total transaction of $95,563.00.
  • On Tuesday, May 21st, Thomas Gad sold 25,000 shares of Y-mAbs Therapeutics stock. The shares were sold at an average price of $12.00, for a total transaction of $300,000.00.

Y-mAbs Therapeutics Price Performance

Y-mAbs Therapeutics stock opened at $12.05 on Friday. The company’s 50 day simple moving average is $13.70 and its 200 day simple moving average is $12.35. Y-mAbs Therapeutics, Inc. has a fifty-two week low of $4.60 and a fifty-two week high of $20.90.

Y-mAbs Therapeutics (NASDAQ:YMABGet Free Report) last released its quarterly earnings data on Tuesday, May 7th. The company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.03). Y-mAbs Therapeutics had a negative return on equity of 21.40% and a negative net margin of 25.64%. The firm had revenue of $19.93 million for the quarter, compared to the consensus estimate of $22.06 million. Equities research analysts predict that Y-mAbs Therapeutics, Inc. will post -0.45 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of YMAB. Acadian Asset Management LLC lifted its stake in Y-mAbs Therapeutics by 24.0% in the third quarter. Acadian Asset Management LLC now owns 811,261 shares of the company’s stock valued at $4,420,000 after buying an additional 157,173 shares in the last quarter. GSA Capital Partners LLP lifted its position in shares of Y-mAbs Therapeutics by 208.3% in the third quarter. GSA Capital Partners LLP now owns 137,299 shares of the company’s stock worth $748,000 after purchasing an additional 92,765 shares in the last quarter. Campbell & CO Investment Adviser LLC acquired a new position in Y-mAbs Therapeutics during the fourth quarter worth $562,000. Trexquant Investment LP boosted its holdings in Y-mAbs Therapeutics by 417.5% during the third quarter. Trexquant Investment LP now owns 76,585 shares of the company’s stock worth $417,000 after purchasing an additional 61,785 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA boosted its holdings in Y-mAbs Therapeutics by 258.2% during the third quarter. Massachusetts Financial Services Co. MA now owns 82,131 shares of the company’s stock worth $448,000 after purchasing an additional 59,201 shares during the last quarter. Institutional investors own 70.85% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on YMAB shares. BMO Capital Markets raised their target price on shares of Y-mAbs Therapeutics from $16.00 to $26.00 and gave the company an “outperform” rating in a research note on Monday, March 4th. Canaccord Genuity Group raised their target price on shares of Y-mAbs Therapeutics from $22.00 to $26.00 and gave the company a “buy” rating in a research note on Monday, March 4th. Finally, HC Wainwright raised their target price on shares of Y-mAbs Therapeutics from $21.00 to $22.00 and gave the company a “buy” rating in a research note on Monday, May 13th. Two equities research analysts have rated the stock with a sell rating and four have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $17.33.

Get Our Latest Research Report on Y-mAbs Therapeutics

About Y-mAbs Therapeutics

(Get Free Report)

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.

Recommended Stories

Insider Buying and Selling by Quarter for Y-mAbs Therapeutics (NASDAQ:YMAB)

Receive News & Ratings for Y-mAbs Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Y-mAbs Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.